BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB:BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced the appointment of Louis Lucido as Interim President of the Company, effective immediately through January 31, 2024, and he will assume the formal role as President on February 1, 2024. Mr. Lucido will remain a Member of the Board of Directors. Additionally, the Company announced that Brady Granier has submitted his letter of resignation as President of BioCorRx Inc. and Chief Executive Officer of BioCorRx Pharmaceuticals, a subsidiary of the Company, effective January 31, 2024. Mr. Granier will continue to serve as a Member of the Company’s Board of Directors. Mr. Granier’s resignation did not arise as a result of any disagreement with the Company nor BioCorRx Pharmaceuticals.
Related news for (BICX)
- BioCorRx Reports Business Update for the Second Quarter of 2024
- BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
- BioCorRx Reports Business Update for 2023
- BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
- BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors